31 results
Cutaneous manifestations associated with myelodysplastic syndrome
 • Myeloid hemopathy with the most frequent skin lesions (20%)
most frequent skin ... polymorphism • Satellite ... differential #diagnosis #dermatology ... #oncology #clinical ... #skin
Diffuse large B cell lymphoma (DLBCL) - Management and Treatment Algorithm

By Matthew Ho, MD PhD @MatthewHoMD

#Diffuse
lymphoma (DLBCL) - Management ... lymphoma #DLBCL #Management ... Treatment #Algorithm #oncology ... #hematology
Treatment Approach to Hodgkin's Lymphoma

By Matthew Ho, MD PhD @MatthewHoMD
With Credit: Dr Sunita Nasta and Dr
Hodgkins #Lymphoma #oncology ... #Hematology #management
Multiple Myeloma - Treatment Algorithm
a) Newly Diagnosed Myeloma: Transplant Eligible
b) Newly Diagnosed Myeloma: Transplant Ineligible

doi: 10.1038/s41408-020-00359-2

#Multiple
Treatment #Algorithm #management ... #hematology #oncology
NOAC / DOAC Pharmacology and Prescribing Cheat Sheet
Novel (or Direct) Oral Anti-Coagulants
 • Rivaroxaban
 • Apixaban
NOAC / DOAC Pharmacology ... #NOAC #DOAC #Pharmacology ... #Prescribing #hematology ... #management #Direct
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
Diagnosis and Management ... acute leukemia Management ... MDS #Diagnosis #Management ... #treatment #hematology ... #oncology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
#management #algorithm ... #pharmacology # ... decisionaid #cardiology #hematology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
Anticoagulation #Management ... #Hematology #Oncology
Behcet's Syndrome - Treatment
Ulcers:
 • Treatment: Topical steroids
 • Prevention: Colchicine
 • Azathioprine for refractory disease
Arthritis:
refractory disease Skin ... Syndrome #Treatment #management ... #pharmacology # ... rheumatology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
#Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology